Deng B, Gao R, Yang B, Lei WB, Xue MF, Wang JS, Zhao P. Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature. World J Clin Cases 2024; 12(24): 5604-5612 [DOI: 10.12998/wjcc.v12.i24.5604]
Corresponding Author of This Article
Peng Zhao, MD, Doctor, Department of Hematology, The Affiliated Hospital of Guizhou Medical University, No. 28 Guiyi Street, Guiyang 550001, Guizhou Province, China. zhaopeng_6786262@hotmail.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 26, 2024; 12(24): 5604-5612 Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5604
Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature
Bo Deng, Department of Haematology, Guizhou Hospital, The First Affiliated Hospital of Sun Yat-sen University, Guiyang 550001, Guizhou Province, China
Rui Gao, Peng Zhao, Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, Guizhou Province, China
Bing Yang, Wen-Bing Lei, Ming-Fang Xue, School of Clinical Medicine, Guizhou Medical University, Guiyang 550001, Guizhou Province, China
Ji-Shi Wang, Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Hematological Institute of Guizhou Province, Guiyang 550001, Guizhou Province, China
Author contributions: Deng B and Gao R contributed to manuscript writing and editing, and data collection; Yang B, Lei WB, Xue MF contributed to data analysis; Wang JS performed the treatment; Zhao P contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Supported byNatural Science Foundation of Guizhou Province, China, No. 397.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All of the authors declare that we have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng Zhao, MD, Doctor, Department of Hematology, The Affiliated Hospital of Guizhou Medical University, No. 28 Guiyi Street, Guiyang 550001, Guizhou Province, China. zhaopeng_6786262@hotmail.com
Received: March 13, 2024 Revised: June 4, 2024 Accepted: June 26, 2024 Published online: August 26, 2024 Processing time: 119 Days and 22.8 Hours
Core Tip
Core Tip: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is currently the only possible way to cure patients with malignant hematologic diseases. In Allo-HSCT, donors have some degree of ABO blood-group incompatibility with the recipient. An outcome of ABO incompatibility caused is pure red cell aplastic anemia (PRCA). We report a 41-year-old female diagnosed with acute myeloid leukemia received a peripheral blood allo-HSCT from an HLA-matched unrelated donor in November 2013. The patient was diagnosed with PRCA three months after allo-HSCT. After failing multiple lines of treatment, daratumumab was requested. After receiving three doses of daratumumab, the patient had a marked reticulocyte response and become transfusion independent.Using of anti-CD38 therapy with daratumumab to target residual host plasma cells is safe and effective, and it can be considered in refractory recipients with PRCA after allo-HSCT secondary to ABO incompatibility.
